Current Report Filing (8-k)
13 June 2018 - 10:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
June 11, 2018
AYTU
BIOSCIENCE, INC.
|
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-38247
|
|
47-0883144
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
373
Inverness Parkway, Suite 206, Englewood, Colorado
|
|
80112
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code:
(720) 437-6580
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
1.01.
|
Entry
into a Material Definitive Agreement
|
On
June 11, 2018, Aytu BioScience, Inc. (the “Company”), entered into a license agreement (the “License Agreement”)
with Magna Pharmaceuticals, Inc. (“Magna”). Pursuant to the License Agreement, Magna granted to the Company an exclusive,
sub-licensable, royalty-bearing license in the United States and Canada related to Zolpimist. The License Agreement may be terminated
by either the Company or Magna on the occurrence of a material breach of the License Agreement and by the Company in its discretion
upon a sixty (60) day prior written notice and the payment of a certain termination fee. As consideration for the license granted,
the Company made a cash payment to Magna. Additionally, the Company will pay Magna certain royalty fees until 2025.
The
Company expects to file the License Agreement as an exhibit to its Annual Report on Form 10-K for the fiscal year ending June
30, 2018, and intends to seek confidential treatment for certain terms and provisions of the License Agreement. The foregoing
description of the License Agreement is qualified in its entirety by reference to the text of the License Agreement, when filed.
|
Item
7.01
|
Regulation
FD Disclosure.
|
On
June 13, 2018, the Company issued a press release announcing the License Agreement. A copy of the press release is attached as
Exhibit 99.1 and incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
The following exhibit is being filed herewith:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AYTU
BIOSCIENCE, INC.
|
|
|
Date:
June 13, 2018
|
By:
|
/s/
David Green
|
|
|
Name:
David Green
|
|
|
Title: Chief Financial Officer
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2024 to May 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From May 2023 to May 2024